Close Menu

hepatitis

NEW YORK (GenomeWeb) – As it continues to aim high with its investigational hepatitis B virus therapy ARC-520, Arrowhead Research this week announced that it has begun testing an even higher dose of the drug in patients in a single-dose Phase IIa trial.

NEW YORK (GenomeWeb) — Beckman Coulter Diagnostics said this month that it has received CE marking for Veris MDx, its "sample-in, results-out" real-time PCR-based molecular diagnostics system, as well as the platform's first assay, a quantitative viral load test for human cytomegalovirus.

Arrowhead Research announced this week that it has completed enrollment and dosing of the first cohort of patients in an ongoing Phase IIb trial of its hepatitis B drug ARC-520.

NEW YORK (GenomeWeb News) — Grifols said today that it has been selected by the Japanese Red Cross Society as a partner in nucleic acid screening of the country's 5.3 million annual blood donations.

Arrowhead Research said this week that it has begun dosing patients in a Phase IIa trial of its hepatitis B treatment ARC-520.

Arrowhead Research this week announced that it has received clearance from regulators in Hong Kong to begin a phase IIa trial of its siRNA-based hepatitis B treatment ARC-520.

Arrowhead Research last month said that it has submitted a regulatory application seeking clearance to begin a phase IIa study of its RNAi-based hepatitis B treatment ARC-520.

Arrowhead Research and Regulus Therapeutics this week announced the presentation of preclinical data on their hepatitis drug candidates.

Tasso, a two-year-old startup focused on point-of-care, blood-based diagnostics, has been awarded a Phase I Small Business Innovation Research grant from the National Institutes of Health to develop a sample preparation and stabilization device for use with HIV viral load quantif

Arrowhead Research this week announced that it has completed enrollment in a phase I trial of its siRNA-based hepatitis B treatment ARC-520, and that available data indicate that the compound is safe to advance into a planned phase IIa study.

Pages

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.